When the 'Holiday Season' Is No Holiday at all for Those With ME/CFS
Is December getting to you? Jody Smith shares some thoughts on some of the struggles that all too often attend this time of year ...
Discuss the article on the Forums.

Physical and genetic causes of autism, bipolar disorder and schizophrenia

Discussion in 'Other Health News and Research' started by Waverunner, Jul 3, 2012.

  1. Waverunner

    Waverunner Senior Member

    Sciencedaily published three abstracts today that summarize new findings in autism, bipolar disorder and schizophrenia. We are moving forward, no question about that, but when will we have a real breakthrough? It becomes more and more clear that autism, bipolar disorder or schizophrenia have physical and genetic causes.

    Charting Autism's Neural Circuitry: Deleting Single Gene Results in Autism-Like Behavior and Immunosuppressant Drug Prevents Symptoms


    ScienceDaily (July 2, 2012) — Deleting a single gene in the cerebellum of mice can cause key autistic-like symptoms, researchers have found. They also discovered that rapamycin, a commonly used immunosuppressant drug, prevented these symptoms.

    The deleted gene is associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition. Since nearly 50 percent of all people with TSC develop autism, the researchers believe their findings will help us better understand the condition's development.
    "We are trying to find out if there are specific circuits in the brain that lead to autism-spectrum disorders in people with TSC," said Mustafa Sahin, Harvard Medical School associate professor of neurology at Boston Children's Hospital and senior author on the paper. "And knowing that deleting the genes associated with TSC in the cerebellum leads to autistic symptoms is a vital step in figuring out that circuitry."
    This is the first time researchers have identified a molecular component for the cerebellum's role in autism. "What is so remarkable is that loss of this gene in a particular cell type in the cerebellum was sufficient to cause the autistic-like behaviors," said Peter Tsai, HMS instructor of neurology and the first author of this particular study.
    These findings were published online July 1 in Nature.
    TSC is a genetic disease caused by mutations in either one of two genes, TSC1 and TSC2. Patients develop benign tumors in various organs in the body, including the brain, kidneys and heart, and often suffer from seizures, delayed development and behavioral problems.
    Researchers have known that there was a link between TSC genes and autism, and have even identified the cerebellum as the key area where autism and related conditions develop.
    In both cases, deleting this gene caused the three main signs of autistic-like behaviors:
    • Abnormal social interactions. The mice spent less time with each other and more with inanimate objects, compared to controls.
    • Repetitive behaviors. The mice spent extended amounts of time pursuing one activity or with one particular object far more than normal.
    • Abnormal communication. Ultrasonic vocalizations, the communication technique among rodents, were highly distressed.
    The researchers also tested learning. "These mice were able to learn new things normally," said Tsai, "but they had trouble with 'reversal learning,' or re-learning what they had learned when their environment changed."
    Tsai and colleagues tested this by training the mice to swim a particular path in which a platform where they could rest was set up on one side of the pool. When the researchers moved the platform to the other side of the pool, the mice had greater difficulty than the control mice re-learning to swim to the other side.
    "These changes in behavior indicate that the TSC1 gene in Purkinje cells, and by extension, the cerebellum, are a part of the circuitry for autism disorders," emphasized Sahin.
    The researchers also found that the drug rapamycin averted the effects of the deleted gene. Administering the drug to the mice during development prevented the formation of autistic-like behaviors.
    Currently, Sahin is the sponsor-principal investigator for an ongoing Phase II clinical trial to test the efficacy of everolimus, a compound in the same family as rapamycin, in improving neurocognition in children with TSC. The trial will be open for enrollment until December 2013.
    "Our next step will be to see how the abnormalities in Purkinje cells affect autism-like development. We don't know how generalizable our current findings are, but understanding mechanisms beyond TSC genes might be useful to autism," said Tsai.
    This study was supported by the National Institutes of Health (R01 NS58956), the John Merck Scholars Fund, Autism Speaks, Nancy Lurie Marks Family Foundation, Children's Hospital Boston Translational Research Program, the Children's Hospital Boston Mental Retardation and Developmental Disabilities Research Center (P30 HD18655).
    Sahin serves as a consultant and site primary investigator for Novartis.

    Success Reported in Treating Autism Spectrum Disorder in Mice


    ScienceDaily (July 2, 2012) — Using a mouse model of autism, researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have successfully treated an autism spectrum disorder characterized by severe cognitive impairment.

    The research team, led by Joe Clark, PhD, a professor of neurology at UC, reports its findings online July 2, 2012, in the Journal of Clinical Investigation, a publication of the American Society for Clinical Investigation.
    The disorder, creatine transporter deficiency (CTD) is caused by a mutation in the creatine transporter protein that results in deficient energy metabolism in the brain. Linked to the X chromosome, CTD affects boys most severely; women are carriers and pass it on to their sons.
    The brains of boys with CTD do not function normally, resulting in severe speech deficits, developmental delay, seizures and profound mental retardation. CTD is estimated to currently affect about 50,000 boys in the United States and is the second-most common cause of X-linked mental retardation after Fragile X syndrome.
    Following CTD's discovery at UC in 2000, researchers at UC and Cincinnati Children's led by Clark discovered a method to treat it with cyclocreatine -- also known as CincY, and pronounced cinci-why -- a creatine analogue originally developed as an adjunct to cancer treatment. They then treated genetically engineered mice as an animal model of the human disease.
    "CincY successfully entered the brain and reversed the mental retardation-like symptoms in the mice, with benefits seen in nine weeks of treatment," says Clark, adding that no harmful effects to the mice were observed in the study. "Treated mice exhibited a profound improvement in cognitive abilities, including recognition of novel objects, spatial learning and memory."
    As a repurposed drug (originally developed for another therapy), CincY has already been through part of the U.S. Food and Drug Administration (FDA) approval process. It is taken orally as a pill or powder.
    UC's Office of Entrepreneurial Affairs and Technology Commercialization has reached agreement with Lumos Pharma, a privately held Austin, Texas, startup company based on UC technology, to develop and commercialize CincY. Lumos Pharma was created with technology licensed from UC's Office of Entrepreneurial Affairs and Technology Commercialization. Its CEO is Rick Hawkins, a 30-year biotech industry veteran. Jon Saxe is its chairman.
    "It has taken many years to get here and I am happy that our efforts have led to this translational effort to make a therapy available to those afflicted with CTD," says Clark. "We look forward with commitment and hope to the day when those patients will benefit from our work."
    The collaboration gained momentum when Lumos Pharma submitted a proposal based on Clark's technology to the National Institutes of Health and was selected as a drug development project partner by the National Center for Advancing Translational Sciences' Therapeutics for Rare and Neglected Diseases (TRND) program. Under TRND's collaborative operational model, project partners form joint project teams with TRND and receive in-kind support from TRND drug development scientists, laboratory and contract resources.
    Lumos Pharma plans to initiate a TRND-supported preclinical development plan, with TRND support continuing through the filing of an Investigational New Drug (IND) application with the FDA prior to beginning a clinical trial. Such a trial would be about three years away, Clark says.
    In addition to Clark, study team members are Yuko Kurosawa, PhD; Ton de Grauw, MD, PhD; Diana Lindquist, PhD; Victor Blanco, PhD; Gail Pyne-Geithman, DPhil; Takiko Daikoku, PhD; James Chambers, PhD; and Stephen Benoit, PhD.
    The research by Clark's team was supported by funding from the National Institutes of Health. The study authors report no conflicts of interest.


    Autism, Schizophrenia and Bipolar Disorder May Share Common Underlying Factors, Family Histories Suggest


    ScienceDaily (July 2, 2012) — New research led by Patrick F. Sullivan, MD, FRANZCP, a medical geneticist at the University of North Carolina School of Medicine, points to an increased risk of autism spectrum disorders (ASDs) among individuals whose parents or siblings have been diagnosed with schizophrenia or bipolar disorder.

    The findings were based on a case-control study using population registers in Sweden and Israel, and the degree to which these three disorders share a basis in causation "has important implications for clinicians, researchers and those affected by the disorders," according to a report of the research published online July 2, 2012 in the Archives of General Psychiatry.
    "The results were very consistent in large samples from several different countries and lead us to believe that autism and schizophrenia are more similar than we had thought," said Dr. Sullivan, professor in the department of genetics and director of psychiatric genomics at UNC.
    Sullivan and colleagues found that the presence of schizophrenia in parents was associated with an almost three times increased risk for ASD in groups from both Stockholm and all of Sweden.
    Schizophrenia in a sibling also was associated with roughly two and a half times the risk for autism in the Swedish national group and a 12 times greater risk in a sample of Israeli military conscripts. The authors speculate that the latter finding from Israel resulted from individuals with earlier onset schizophrenia, "which has a higher sibling recurrence."
    Bipolar disorder showed a similar pattern of association but of a lesser magnitude, study results indicate.
    "Our findings suggest that ASD, schizophrenia and bipolar disorder share etiologic risk factors," the authors state. "We suggest that future research could usefully attempt to discern risk factors common to these disorders."
    TheChosenOne and SickOfSickness like this.
  2. Glynis Steele

    Glynis Steele Senior Member

    Newcastle upon Tyne UK
    Thanks for these Waverunner, here is another one, this time regarding rapamycin and alzheimer's. The downside is that rapamycin is rather expensive and is currently used to prevent rejection in organ transplant's. I saw a couple of years ago that in kids with tuberous sclerosis it was reducing their autistic traits.

    ScienceDaily (June 29, 2012) — Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer's disease. Texas scientists seeking a way to prevent this decline reported exciting results this week with a drug that has Polynesian roots.

    The researchers, appointed in the School of Medicine at The University of Texas Health Science Center San Antonio, added rapamycin to the diet of healthy mice throughout the rodents' life span. Rapamycin, a bacterial product first isolated from soil on Easter Island, enhanced learning and memory in young mice and improved these faculties in old mice, the study showed.

    "We made the young ones learn, and remember what they learned, better than what is normal," said Veronica Galvan, Ph.D., assistant professor of physiology at the Barshop Institute for Longevity and Aging Studies, part of the UT Health Science Center. "Among the older mice, the ones fed with a diet including rapamycin actually showed an improvement, negating the normal decline that you see in these functions with age."

    The drug also lowered anxiety and depressive-like behavior in the mice, Dr. Galvan said. Anxiety and depression are factors that impair human cognitive performance. Lead author Jonathan Halloran conducted scientifically reliable tests to accurately measure these cognitive components in the rodents.

    Rapamycin acts like an antidepressant
    "We found rapamycin acts like an antidepressant -- it increases the time the mice are trying to get out of the situation," she said. "They don't give up; they struggle more."
    The reductions of anxiety and depressive-like behavior in rapamycin-treated mice held true for all ages tested, from 4 months of age (college age in human years) to 12 months old (the equivalent of middle age) to 25 months old (advanced age).
    Feel-good chemicals elevated
    The researchers measured levels of three "happy, feel-good" neurotransmitters: serotonin, dopamine and norepinephrine. All were significantly augmented in the midbrains of mice treated with rapamycin. "This is super-interesting, something we are going to pursue in the lab," Dr. Galvan said.
    Dr. Galvan and her team published research in 2010 showing that rapamycin rescues learning and memory in mice with Alzheimer's-like deficits. The elevation of the three neurotransmitters, which are chemical messengers in the brain, may explain how rapamycin accomplished this, Dr. Galvan said.
    Rapamycin is an antifungal agent administered to transplant patients to prevent organ rejection. The drug is named for Rapa Nui, the Polynesian title for Easter Island. This island, 2,000 miles from any population centers, is the famed site of nearly 900 mysterious monolithic statues.
    This study became available online June 28 as a manuscript in press in the journal Neuroscience.

    Full article here:

    Waverunner likes this.
  3. Glynis Steele

    Glynis Steele Senior Member

    Newcastle upon Tyne UK
    From pubmed:

    Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.

    Ehninger D, Silva AJ.

    DZNE, German Center for Neurodegenerative Diseases, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany. Dan.Ehninger@dzne.de

    Tuberous sclerosis (TSC) is a genetic disorder caused by heterozygous mutations in the TSC1 or TSC2 genes and is associated with autism spectrum disorders (ASD) in 20-60% of cases. In addition, altered TSC/mTOR signaling is emerging as a feature common to a subset of ASD. Recent findings, in animal models, show that restoration of the underlying molecular defect can improve neurological dysfunction in several of these models, even if treatment is initiated in adult animals, suggesting that pathophysiological processes in the mature brain contribute significantly to the overall neurological phenotype in these models. These findings suggest that windows for therapeutic intervention in ASD could be wider than thought previously.
  4. Waverunner

    Waverunner Senior Member

    Very interesting, Glynis. It might be interesting to know, that Rapamycin is one of the few drugs of choice that seems to be implicated in life extension. Its interference with mTOR seems to play a big role in preventing disease and extending human life span.
    Glynis Steele likes this.
  5. RustyJ

    RustyJ Contaminated Cell Line 'RustyJ'

    Mackay, Aust
    What about cyclocreatine? Anyone know anything about it? Maybe it's worth a try.
  6. wastwater

    wastwater Senior Member

    Bump for mTOR rapamycin and Easter island
    Last edited: Apr 11, 2017

See more popular forum discussions.

Share This Page